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Darbepoetin alfa is an engineered and hyperglycosylated analog of recombinant human erythropoietin
(EPO) which is used as a drug in treating anemia in patients with chronic kidney failure and cancer. This
study desribes the secretory expression of a codon-optimized recombinant form of darbepoetin alfa in
Leishmania tarentolae T7-TR. Synthetic codon-optimized gene was ampliﬁed by PCR and cloned into the
pLEXSY-I-blecherry3 vector. The resultant expression vector, pLEXSYDarbo, was puriﬁed, digested, and
electroporated into the L. tarentolae. Expression of recombinant darbepoetin alfa was evaluated by ELISA,
reverse-transcription PCR (RT-PCR), Western blotting, and biological activity. After codon optimization,
codon adaptation index (CAI) of the gene raised from 0.50 to 0.99 and its GC% content changed from 56%
to 58%. Expression analysis conﬁrmed the presence of a protein band at 40 kDa. Furthermore, reticu-
locyte experiment results revealed that the activity of expressed darbepoetin alfa was similar to that of
its equivalent expressed in Chinese hamster ovary (CHO) cells. These data suggested that the codon
optimization and expression in L. tarentolae host provided an efﬁcient approach for high level expression
of darbepoetin alfa.
© 2015 Elsevier Inc. All rights reserved.1. Introduction
Darbepoetin alfa is an engineered human erythropoietin (EPO)
analog with two additional sialic acid chains. It has been designed
to contain ﬁve N-linked glycosylation sites (Asn 24, 30, 38, 83, 88),
two more than its natural variant. The inserted new positions have
been shown to have no interference with its receptor binding
ability or have no effect on the conformation of EPO [1,2]. The drug
stimulates the bone marrow to produce more red blood cells. Thus
it is used for treatment of anemia in patients with chronic kidneymehr), samaneh.mostafavi@
midinia).failure or special types of cancer [3]. Darbepoetin alfa with a mo-
lecular weight of approximately 40 kDa has longer circulating half-
life and greater in vivo bioactivity than the EPO. Due to these
properties, it can be administered less frequently to attain a proper
biological inﬂuence [4]. In 2000, the darbepoetin alfa gene was
constructed through the site-directed mutagenesis performed on
the EPO gene and was expressed in CHO cells by Egrie and his co-
workers [5]. Darbepoetin alfa was approved in 2001 by the Food
and Drug Administration (FDA) for the treatment of anemia. It is
marketed by the Amgen company under the trade name of Aranesp
and had more than 6$ billion sales in 2006. Therapeutic applica-
tions of darbepoetin alfa have extended interests for improving and
reﬁningmethods for its manufacture. Expression and production of
recombinant proteins in CHO cells generally have a number of
drawbacks including low yield, complex nutritional needs, high
puriﬁcation cost, and possibility of product contamination.
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ability to solve these problems was considered. Among the Trypa-
nomatidae family, Leishmania tarentolae known to be a non-
pathogenic parasite, has recently been introduced and employed
as a potential eukaryotic expression host [6,7]. L. tarentolae is rich in
glycoproteins and its glycosylation pattern is similar to that of
mammalian system that includes complex-type oligosaccharides
[8]. Moreover, L. tarentolae has some advantages, including simple
nutrient requirements, straightforward handling, rapid growth
rate, and also potential for large scale production of recombinant
proteins. These features make L. tarentolae an appealing and potent
host for biotechnological applications [9]. To date, several suc-
cessful examples of using L. tarentolae in the expression proteins,
such as EPO [10], interferon-gamma (IFN-g) [11], and IgG [12] were
also reported. The data presented here describe the cloning and
expression of recombinant darbepoetin alfa in L. tarentolae T7-TR
secretory expression system. This is the ﬁrst report on the pro-
duction of darbepoetin alfa in L. tarentolae.2. Materials and methods
2.1. Hosts, plasmid and chemicals
L. tarentolae T7-TR strain, pLEXSY-I-blecherry3 vector (Cat.-No.
EGE-1410), in addition to brain heart infusion (BHI) medium and all
required materials were purchased from Jena Bioscience (Jena
Bioscience, Jena, Germany). All chemicals were also obtained from
SigmaeAldrich (St. Louis, USA). Darbepoetin alfa with the trade
name of Aranesp was prepared from Amgen (Thousand Oaks, CA,
USA).2.2. Codon optimization and gene synthesis
The DNA sequence of darbepoetin alfa was obtained from a
published sequence [5,13] and used to gene design. Codon opti-
mization was done by the online program Optimizer (http://
genomes.urv.es/OPTIMIZER) based on the codon usage table of
L. tarentolae (http://www.kazusa.or.jp/codon). Native and codon
optimized darbepoetin alfa genes were synthesized and cloned into
the pGH cloning vector (BIONEER, Korea).2.3. Construction of expression plasmid for darbepoetin alfa
The expression cassette was constructed using components of
pLEXSY-I-blecherry3 vector (Jena Bioscience, Cat. No. EGE-1410).
The native and synthetic codon optimized darbepoetin alfa genes
were ampliﬁed by polymerase chain reaction (PCR) technique from
the pGH plasmid. The forward and reverse primers, which con-
tained restriction sties in 50terminus (underlined) were; Darbo-
forward: 50-ATTCTAGACGCGCCGCCG-30and Darbo-reverse: 50-
AGGTACCGCGGTCGCCC-30. The restriction sites in forward and
reverse primers correspond to KpnI and XbaI enzymes, respectively.
PCR was performed by thermal cycler (Eppendorf, Germany) under
standard protocol consisted of a 94 C for 5 min, 30 cycles of 94 C
for 1 min, 56 C for 1 min, 72 C for 40 s and 72 C for 10 min as a
ﬁnal extension step. The obtained PCR product (503 bp) was
digested with KpnI and XbaI, gel puriﬁed and ligated into a digested
pLEXSY-I-blecherry3 expression vector. Then the ligation reaction
was transformed into Escherichia coli TOP10. The resultant
expression construct (pLEXSYDarbo) was puriﬁed from the re-
combinant colonies using an alkaline lysis method (Qiagen Plasmid
Maxi Kit), veriﬁed by restriction enzyme digestion and DNA
sequencing.2.4. Transfection of L. tarentolae T7-TR
Initially, L. tarentolae T7-TR was grown as a static suspension in
BHI broth medium containing 5 mg/ml hemin, 100 mg/ml penicillin,
100 mg/ml streptomycin, and 100 mg/ml hygromycin at pH 7.2 and
26 C. Afterwards, pLEXSYDarbo plasmid was digested with SwaI
restriction enzyme and the 6000 bp fragment containing darbe-
poetin alfa gene was gel puriﬁed. For transfection, log-phase par-
asites with OD600 ¼ 2.0 resuspended in 400 ml of ice-cold
electroporation buffer (21 mM HEPES, 137 mM NaCl, 5 mM KCl,
0.7 mM Na2HPO4, 6 mM glucose, pH 7.5), mixed with approxi-
mately 15 mg of the linearized expression cassette and then elec-
troporated using a Bio-Rad Gene Pulser at 500 mF, 450 V and two
pulses. The electroporated promastigotes were incubated in BHI
broth medium at 26 C for 24 h without any drug. Selection of
single colonies was done by growth on solidiﬁed BHI medium
containing 100 mg/ml nourseothricin (NTC) and 100 mg/ml bleo-
mycin [14].
2.5. Conﬁrmation and screening of transfectants by diagnostic PCRs
To conﬁrm the homologues recombination integration of the
cassette containing darbepoetin alfa into the odc locus of
L. tarentolae T7-TR genome in transfectant strains, different diag-
nostic PCRs were performed. For this purpose, primer pairs
including one primer hybridizing within the expression cassette
and one primer hybridizing to an odc sequence not present on the
plasmid were applied. The information related to the primers is
shown in Table 1. Genomic DNA from 5 ml of a dense culture (OD
approx. 2e3) was prepared by conventional phenol/chloroform
extraction. The PCR reactions resulted in a characteristic fragment
for each PCR (Table 1), which was not observed in control reactions.
Diagnostic PCR, including darbepoetin alfa-speciﬁc primer was also
performed.
2.6. Expression and puriﬁcation
For secretory expression of recombinant protein, transfected
L. tarentolae cells were grown in BHI medium supplemented with
hemin, penicillin, streptomycin, bleomycin, and NTC at 26 C as
static suspension culture in TC ﬂasks. The T7 driven transcription
was induced with 10 mg/ml tetracycline for 72 h after inoculation.
The induction was also monitored by the measurement of ﬂuo-
rescence at 590 nm (excitation) and 620 nm (emission). Expression
of recombinant darbepoetin alfa was conﬁrmed by ELISA, reverse-
transcription PCR (RT-PCR) and Western blotting. Recombinant
L. tarentolae cells were harvested from a 3-day cell culture by
centrifugation at 3500 rpm for 10 min and supernatant of the cell
culture was removed and concentrated. The precipitated sample
was dissolved in 1X SDS polyacrylamide gel electrophoresis (SDS-
PAGE) sample buffer and then boiled for 5 min. Samples from both
wild and transgenic L. tarentolae was separated on 12% (w/v) SDS-
PAGE gel. For western blot, the resolved proteins were transferred
to the PVDF membrane using a wet blotting system and incubated
with TBST solution containing 3% bovine serum albumin (BSA) for
overnight at 4 C. The membrane was washed three times with
TBST and reacted with anti-EPO antibody (2 mg; rabbit polyclonal
antibody to EPO; Abcam, UK) as the ﬁrst antibody for 2 h at room
temperature. After three washes, goat anti-rabbit horseradish
peroxidase (HRP)econjugated IgG was added and incubated for
1 h at room temperature. The band of target protein was detected
using 3, 30-Diaminobezidine (DAB) and H2O2. For RT-PCR reaction,
RNA samples were extracted according to the manufacturer's in-
structions (Jena Bioscience, Jena, Germany). The cDNA synthesis
was done through cDNA synthesis kit (Premix kit, BioNEER, Korea)
Table 1
Nucleotide sequences of primers used in diagnostic PCRs.
Primer Sequence (50/30) Annealing temp. Amplicon size (bp)
50odc-utr1 (aprt)
A1304 TCCGCCATTCATGGCTGGTG 60 C 1100
A1715 TATTCGTTGTCAGATGGCGCAC
Blecherry- 30odc
A708 GGATCCACCGCATGGCCAAGTTGACCA 60 C 2700
P1510 GTGGTGCACCCATAGTAGAGGTGC
Darbepoetin alfa gene
Darbo-F ATTCTAGACGCGCCGCCG 56 C 500
Darbo-R AGGTACCGCGGTCGCCC
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(annealing temperature 62 C). To purify the recombinant protein,
concentrated supernatant of L. tarentolae culture was applied to a
Ni-NTA afﬁnity column (Qiagen, Germany) according to the man-
ufacture's instruction. The column was washed with 3 column
volumes of the 50 mM TriseHCl buffer (pH 7.0) containing 50 mM
imidazole, and then darbepoetin alfa was eluted with an elution
buffer (50 mM TriseHCl, 50 mM NaCl, 10 mM EDTA, 500 mM
imidazole, pH 7.0).
2.7. In vivo bioassay test
Inbred female BALB/c mice weighting 18e22 g, and about 6e8
weeks of day were prepared from Research and Production Com-
plex of Pasteur Institute of Iran, Karaj, Iran and housed under
standardized conditions (25 C, 12 h light/12 h darkness, humidity
50e55%) with free access to pelleted food and tap water. Each was
received identical amount of puriﬁed darbepoetin alfa by subcu-
taneous injection (5 mg/kg in 100 ml). Peripheral blood was har-
vested every 24 h and heamtocrite was measured using a
microhaematocrit centrifuge and Hematology Analyzer (Sysmex,
Kobe, Japan).
3. Results
3.1. Design of darbepoetin alfa gene for optimal expression in
L. tarentolae
The synthetic darbepoetin alfa gene was assembled based on
the L. tarentolae codon usage. The native and codon-optimized
constructs included the ORF encoding darbepoetin alfa and a C-
terminal 6xHis-tag to facilitate puriﬁcation. The alignment of DNA
and amino acid sequences of native and designed gene were
depicted (see Fig.1). As seen, amino acid sequences were absolutely
identical. The optimized gene had 79.57% of identity with respect to
the wild type. To achieve the maximal resemblance with highly
expressed L. tarentolae genes, the codon composition of synthetic
genewas reprogrammed using themost frequently used codons for
L. tarentolae. Out of 145 amino acids in the sequence of darbepoetin
alfa, 56 codons were modiﬁed in codons highly preferred by
L. Tarentolae (see Fig. 1). Upon codon optimization, codon adapta-
tion index (CAI) increased from 0.50 to 0.99 and GC% content was
changed from 56% to 58%. Additionally, within synthetic codon-
optimized gene, the splice sites, polyadenylation signal, instability
elements, and cis-acting sites were removed.
3.2. Construction of pLEXSYDarbo expression cassette
The native darbepoetin alfa construct was similar to the codon-
optimized variant in all respect, but its results were not shown. The
synthetic darbepoetin alfa genes were isolated by PCR on the pGH
plasmid. A single 503 bp band was observed on agarose gel after
electrophoresis. The obtained PCR product was cut with KpnI andXbaI restriction enzymes, extracted from the gel and ligated into
pLEXSY vector. The pLEXSYDarbo expression cassette includes KpnI
and XbaI cloning sites downstream of the signal peptide which
originally belongs to the Leishmania mexicana secreted acid phos-
phatase (LMSAP) and a C-terminal His-tag for puriﬁcation. The
correct gene cloning was conﬁrmed by restriction analysis and DNA
sequencing.
3.3. Conﬁrmation of integration into the expression cassette
The recombinant pLEXSYDarbo plasmid was prepared in large
scale, linearized with SwaI restriction enzyme and transfected into
L. tarentolae T7-TR cells by electroporation. The transfectnats were
selected by plating on BHI agar medium containing 100 mg/ml
bleomycin and 100 mg/ml NTC. Individual clones were selected and
transferred into culture plates and then into tissue culture ﬂasks.
Integration of the expression construct into the ssu locus of re-
combinant cells was conﬁrmed by PCR analysis which generated 1.1
(Fig. 2a) and 2.7 kbp (Fig. 2b) fragments. Ampliﬁcaltion of these
fragments were not obtained in genomic DNA of the wild type
parasite (Fig. 2c). Moreover, a PCR reaction with darbepoetin alfa
speciﬁc primers was done. The expected PCR product size (503 bp)
was only seen from transfected cells.
3.4. Expression analysis and puriﬁcation of recombinant
darbepoetin alfa
The secretory expression of darbepoetin alfa protein in
L. tarentolae T7-TR host was investigated by ELISA, RT-PCR, and
Western blotting techniques. The selected recombinant clone
showed detectable expression data in comparison with wild type
cell by ELISA (data not shown). In order to verify mRNA synthesis in
Leishmania host, RT-PCR was performed by darbepoetin alfa spe-
ciﬁc primers. Transfected cells were indicated to have a dominant
band of 503 bp on agarose gel whereas in wild cells, this fragment
was not detected (see Fig. 3a). The puriﬁed protein with an ex-
pected size of 40 kDa was achieved on SDS-PAGE gel (Fig. 3b).
Western blot method certainly conﬁrmed that the band which was
observed in SDS-PAGE was target protein (Fig. 3c). Furthermore,
Western blotting results revealed that the expressed darbepoetin
alfawas also homogeneous. The expression level in L. tarentolae T7-
TRwas determined to be 11mg/L. The yield of puriﬁed protein from
the codon-optimized construct was 64%. The procedure resulted in
puriﬁcation of 7.0 mg protein from 1 L of suspension culture.
3.5. Potency of produced darbepoetin alfa
The potency of recombinant darbepoetin alfa in increasing he-
matocrit was quantiﬁed and compared with Aranesp. The result of
in vivo bioassay was depicted in Fig. 4. As can be found, the content
of reticulocyte increase for both produced darbepoetin alfa in
L. tarentolae and also Aranesp was nearly similar.
Fig. 1. DNA and amino acid sequence alignment of darbepoetin alfa native gene and its synthetic variant designed for optimal expression in L. tarentolae host.
Fig. 2. (A) Diagnostic PCR on genomic DNA of recombinant L. tarentolae cells with A1304 and A1715 primers. Lane M: DNA molecular weight marker; Lane 1: 1.1 kbp PCR product;
Lane 2: Wild type parasite (B) Diagnostic PCR on genomic DNA of recombinant L. tarentolae cells with A708 and P1510 primers. Lane M: DNA molecular weight marker; Lane 1:
2.7 kbp PCR product; Lane 2: Wild type parasite (C) Diagnostic PCR on genomic DNA of recombinant L. tarentolae cells with Darbo-F and Darbo-R primers. Lane M: DNA molecular
weight marker; Lane 1: 500 bp PCR product; Lane 2: Wild type parasite.
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Darbepoetin alfa, a synthetic and hyperglycosylated form of
human erythropoietin, has an extended circulating half-life andthus a higher in vivo bioactivity than EPO [15,16]. L. tarentolae is a
unicelluar non-pathogenic parasite of white spotted wall gecko,
Tarentola annularis, which have recently attracted a huge attention
as a feasible eukaryotic expression system for the expression of
Fig. 3. Expression analysis of recombinant darbepoetin alfa produced in L. tarentolae T7-TR by RT-PCR, SDS-PAGE and Western blotting methods. (A) RT-PCR. Lane M: DNA mo-
lecular weight marker; Lane 1: wild parasite as negative control; Lane 2: transfected cell with darbepoetin alfa expression cassette. (B) SDS-PAGE. Lane M: protein marker; Lane 1:
puriﬁed darbepoetin alfa. (C) Western blot. Lane M: protein marker; Lane 1: transfected cell with codon-optimized darbepoetin alfa; Lane 2: transfected cell with native darbepoetin
alfa.
Fig. 4. In vivo bioactivity of recombinant darbepoetin alfa. Blood samples were
collected daily and reticulocytes were detected.
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host has some unique advantages including higher speciﬁc growth
rate compared to mammalian cells, simple and low cost nutrient
needs, the least required biosafety level for humans, possibility to
introduce several copies of a foreign gene into the parasite genome,
and production of recombinant proteins with a mammalian-like N-
glycosylation pattern. These advantages, besides the possibility of
constitutive or inducible protein production, make the L. tarentolae
a highly potential host for heterologous expression of recombinant
proteins [17e20]. In the present study, we established a heterolo-
gous secretory expression system for high yield production of re-
combinant darbepoetin alfa in L. tarentolae T7-TR. However, the
presence of rare codons could hamper the expression of darbe-
poetin alfa, due to inefﬁcient translation in the host. A strategy to
improve the codon translation efﬁciency by L. tarentolae was the
construction of a codon-optimized synthetic gene. Therefore, we
optimized codons of darbepoetin alfa according to the codon usage
of L. tarentolae to achieve the highest possible level of expression.
After codon optimization, CAI raised from 0.50 to 0.99 and the GC%
content underwent a change from 56% to 58%, indicating optimal
adaptation and suggesting efﬁcient translation. Higher CAI value
and GC content which was closer to that of L. tarentolae, alsoprovided a good estimation for high level expression. Expression
analysis showed the presence of a protein band at 40 kDa. Ulti-
mately, reticulocyte experiment results displayed that the activity
of optimized darbepoetin and that of Aranesp was identical.
Therefore, all the obtained data suggested an acceptable functional
and structural proﬁle for recombinant codon-optimized darbe-
poetin alfa which is comparable to those of the native protein. In
2002, Breitling et al. reported the study on expression of EPO in
L. tarentolae [10]. Although they took advantage of the native
sequence, the expression level was achieved to be 30 mg/L of
suepension culture. The reported expression level for proteins in
L. tarentolae usually varied between 0.1 and 30 mg/L. For example,
the expression level for green ﬂuorescent protein (GFP) [22], IFN-g
[11], and tissue plasminogen activator (t-PA) [21] were reported to
be 30.0, 9.5, and 0.17 mg/mL, respectively. In this study a codon-
optimized ORF was used that gave an expression level of 11 mg/L
of culture medium. This was more than double what was reported
in CHO cells (4.5 mg/L). The expression of native darbepoetin alfa
gene was also measured to be 6 mg/L of culture medium. Hence, it
can be concluded that the codon optimization could be adopted as a
good approach to enhance production yield and, as a result to
diminish the production cost of the protein, i.e. higher protein yield
from the same conditions. What is more, the lower expression of
darbepoetin alfa in comparisonwith the EPO in L. tarentolaemay be
rooted in the lower number of gene copies integrated into the
host's genome. Based on the reports of Jena Bioscience, there are
numerous examples of highly expressed genes with native codons
and thus, using optimized synthetic gene does not always guar-
antee a higher expression level. It is proper to mention that pro-
duction yield of the recombinant protein could be enhanced by
further optimization of expression conditions such as culture
method (static or agitated suspension cultures) and induction pa-
rameters (tetracycline concentration, time point of induction and
induction time) using one-variable-at-a-time studies or statistical
techniques e.g. response surface methodology (RSM) [23,24]. We
are currently pursuing this subject in our laboratory.5. Conclusion
Taken together, we generated a recombinant L. tarentolae strain
A. Kianmehr et al. / Protein Expression and Puriﬁcation 118 (2016) 120e125 125expressing the codon-optimized darbepoetin alfa. Our results
suggested that L. tarentolae can be used as a host for production of
hyperglycosylated proteins like darbepoetin alfa and that still
codon optimization might have a boosting effect for protein
expression in L. tarentolae. The presented work is the ﬁrst report on
secretory expression of codon-optimized darbepoetin alfa in
L. tarentolae T7-TR.
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